Mefloquine, artesunate and mefloquine-artesunate in the treatment of Schistosoma mansoni and Schistosoma haematobium infections in Côte d?Ivoire

Swiss Tropical Institute (Switzerland)0 个研究点目标入组 120 人开始时间: 2008年10月17日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Schoolchild (aged 8 - 16 years, either sex) infected with S. mansoni (study 1) or S. haematobium (study 2), as assessed by the presence of egg(s) in the stool (S. mansoni) or urine (S. haematobium)
•2. Weight of schoolchild greater than 25 kg
•3. Able and willing to be examined by a physician at the beginning of the study and at the end of study (3 weeks post-treatment)
•4. Able and willing to provide multiple stool or urine samples at the beginning and end of study
•5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment
•6. Absence of psychiatric disorders and epilepsy
•7. No known or reported hypersensitivity to mefloquine and/or artesunate
•8. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease
•9. Signed written informed consent sheet by parents/legual guardians and child
•10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a female nurse (interview and pregnancy test if need be), upon initial clinical assessment

•1. Schoolchild who has clinical malaria (i.e. axillary temperature greater than or equal to 37.5°C and parasitaemia, as assessed by thick and thin blood film examination)
•2. Pregnancy first trimester
•3. Presence of any abnormal medical condition, judged by the study physician
•4. History of acute or severe chronic disease, including hepato-splenic schistosomiasis, macrohaematuria and bloody stools
•5. Psychiatric disorders and epilepsy
•6. Use of artesunate, artemether, any artemisinin-based combination therapy, mefloquine or praziquantel within the past 7 days
•7. Attending other clinical trials during the study

发起方

Swiss Tropical Institute (Switzerland)